The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

The adenosine diphosphate (ADP) receptor P2RY12 (purinergic receptor P2Y, G protein coupled, 12) plays a critical role in platelet aggregation, and P2RY12 inhibitors are used clinically to prevent cardiac and cerebral thrombotic events. Extracellular ADP has also been shown to increase osteoclast (OC) activity, but the role of P2RY12 in OC biology is unknown. Here, we examined the role of mouse P2RY12 in OC function. Mice lacking P2ry12 had decreased OC activity and were partially protected from age-associated bone loss. P2ry12-/- OCs exhibited intact differentiation markers, but diminished resorptive function. Extracellular ADP enhanced OC adhesion and resorptive activity of WT, but not P2ry12-/-, OCs. In platelets, ADP stimulation of P2RY12 resulted in GTPase Ras-related protein (RAP1) activation and subsequent αIIbβ3 integrin activation. Likewise, we found that ADP stimulation induced RAP1 activation in WT and integrin β3 gene knockout (Itgb3-/-) OCs, but its effects were substantially blunted in P2ry12-/- OCs. In vivo, P2ry12-/- mice were partially protected from pathologic bone loss associated with serum transfer arthritis, tumor growth in bone, and ovariectomy-induced osteoporosis: all conditions associated with increased extracellular ADP. Finally, mice treated with the clinical inhibitor of P2RY12, clopidogrel, were protected from pathologic osteolysis. These results demonstrate that P2RY12 is the primary ADP receptor in OCs and suggest that P2RY12 inhibition is a potential therapeutic target for pathologic bone loss.

[1]  P. Vestergaard,et al.  Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. , 2012, International journal of cardiology.

[2]  S. Robinson,et al.  The role of β3-integrins in tumor angiogenesis: context is everything. , 2011, Current opinion in cell biology.

[3]  M. Bauer,et al.  Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. , 2011, Shock.

[4]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[5]  N. Jørgensen,et al.  Bone phenotypes of P2 receptor knockout mice. , 2011, Frontiers in bioscience.

[6]  S. Dixon,et al.  P2 receptor expression, signaling and function in osteoclasts. , 2011, Frontiers in bioscience.

[7]  M. Rogers,et al.  The regulation of osteoclast function and bone resorption by small GTPases , 2011, Small GTPases.

[8]  W. Junger,et al.  Immune cell regulation by autocrine purinergic signalling , 2011, Nature Reviews Immunology.

[9]  S. Heptinstall,et al.  Mode of action of P2Y12 antagonists as inhibitors of platelet function , 2010, Thrombosis and Haemostasis.

[10]  M. A. Ajmone-Cat,et al.  TGF‐β and LPS modulate ADP‐induced migration of microglial cells through P2Y1 and P2Y12 receptor expression , 2010, Journal of neurochemistry.

[11]  K. Ravichandran.  Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums , 2010, The Journal of experimental medicine.

[12]  A. Schwab,et al.  Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis , 2010, Science Signaling.

[13]  W. Zou,et al.  Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization. , 2010, The Journal of clinical investigation.

[14]  J. Schneider,et al.  Dissection of platelet and myeloid cell defects by conditional targeting of the β3‐integrin subunit , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  A. Michelson.  New P2Y12 antagonists , 2009, Current opinion in hematology.

[16]  W. Zou,et al.  CD47 regulates bone mass and tumor metastasis to bone. , 2009, Cancer research.

[17]  J. Bos,et al.  PKA and Epac1 regulate endothelial integrity and migration through parallel and independent pathways. , 2008, European journal of cell biology.

[18]  F. Di Virgilio,et al.  Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca2+ Increases and Cytokine Secretion1 , 2008, The Journal of Immunology.

[19]  F. Di Virgilio,et al.  Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase , 2008, PloS one.

[20]  E. Bradley,et al.  Pathway crosstalk between Ras/Raf and PI3K in promotion of M‐CSF‐induced MEK/ERK‐mediated osteoclast survival , 2008, Journal of cellular biochemistry.

[21]  E. Morgan,et al.  APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice , 2008, Journal of cellular biochemistry.

[22]  Kazuhide Inoue,et al.  Akt activation is involved in P2Y12 receptor‐mediated chemotaxis of microglia , 2008, Journal of neuroscience research.

[23]  D. Gale,et al.  Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. , 2008, Blood.

[24]  Joshua D. Dilley,et al.  Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. , 2008, The American journal of pathology.

[25]  S. Teitelbaum,et al.  The osteoclast: friend or foe? , 2008, Annual review of pathology.

[26]  S. Robson,et al.  Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. , 2007, The American journal of pathology.

[27]  G. Burnstock,et al.  Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. , 2007, Endocrinology.

[28]  M. Dailey,et al.  Purines induce directed migration and rapid homing of microglia to injured pyramidal neurons in developing hippocampus , 2007, Glia.

[29]  Kazuhide Inoue,et al.  Involvement of P2X4 and P2Y12 receptors in ATP‐induced microglial chemotaxis , 2007, Glia.

[30]  R. Czajkowski,et al.  Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long‐term serum‐deprived glioma C6 cells , 2007, The FEBS journal.

[31]  A. Navarro,et al.  The mitochondrial energy transduction system and the aging process. , 2007, American journal of physiology. Cell physiology.

[32]  Su‐Li Cheng,et al.  Accentuated Ovariectomy‐Induced Bone Loss and Altered Osteogenesis in Heterozygous N‐Cadherin Null Mice , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  W. Gan,et al.  The P2Y12 receptor regulates microglial activation by extracellular nucleotides , 2006, Nature Neuroscience.

[34]  P. Hordijk,et al.  Epac1‐Rap1 signaling regulates monocyte adhesion and chemotaxis , 2006, Journal of leukocyte biology.

[35]  K. Jacobson,et al.  Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. , 2006, Biochemical pharmacology.

[36]  Yunfeng Feng,et al.  Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. , 2006, Cancer research.

[37]  Pascual Ferrara,et al.  The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Kanakura,et al.  Critical role of ADP interaction with P2Y12 receptor in the maintenance of αIIbβ3 activation: association with Rap1B activation , 2006, Journal of thrombosis and haemostasis : JTH.

[39]  A. Graybiel,et al.  The small GTPase Rap1b regulates the cross talk between platelet integrin α2β1 and integrin αIIbβ3 , 2006 .

[40]  K. Conley,et al.  Reduced mitochondrial coupling in vivo alters cellular energetics in aged mouse skeletal muscle , 2005, The Journal of physiology.

[41]  S. Teitelbaum,et al.  Critical Role of β3 Integrin in Experimental Postmenopausal Osteoporosis , 2005 .

[42]  S. Teitelbaum,et al.  αvβ3 and macrophage colony‐stimulating factor: partners in osteoclast biology , 2005 .

[43]  C. Gachet,et al.  Interplay between P2Y(1), P2Y(12), and P2X(1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. , 2005, Blood.

[44]  David Piwnica-Worms,et al.  Real-time imaging of ligand-induced IKK activation in intact cells and in living mice , 2005, Nature Methods.

[45]  D. Billadeau,et al.  Protein Kinase D1 and the β1 Integrin Cytoplasmic Domain Control β1 Integrin Function via Regulation of Rap1 Activation , 2005 .

[46]  S. M. Sims,et al.  P2Y6 Nucleotide Receptors Activate NF-κB and Increase Survival of Osteoclasts* , 2005, Journal of Biological Chemistry.

[47]  P. Presek,et al.  P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets , 2005, Thrombosis and Haemostasis.

[48]  T. Fischer,et al.  Rap1b is required for normal platelet function and hemostasis in mice. , 2005, The Journal of clinical investigation.

[49]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[50]  Janet E. Paulsen,et al.  Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae. , 2004, Biochemical and biophysical research communications.

[51]  Jianguo Jin,et al.  Akt Activation in Platelets Depends on Gi Signaling Pathways* , 2004, Journal of Biological Chemistry.

[52]  S. Kunapuli,et al.  Central role of the P2Y12 receptor in platelet activation. , 2004, The Journal of clinical investigation.

[53]  M. Tomasson,et al.  Platelet and osteoclast β3 integrins are critical for bone metastasis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. K. Harden,et al.  Purification and functional reconstitution of the human P2Y12 receptor. , 2003, Molecular pharmacology.

[55]  A. Zallone,et al.  Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin , 2003, The Journal of cell biology.

[56]  P. Conley,et al.  P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. , 2003, The Journal of clinical investigation.

[57]  P. Moreira,et al.  Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. , 2003, Diabetes.

[58]  J. Herbert,et al.  P2Y12, A New Platelet ADP Receptor, Target of Clopidogrel , 2003, Seminars in vascular medicine.

[59]  A. Zallone,et al.  c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation , 2003 .

[60]  L. Parise,et al.  Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. , 2003, Blood.

[61]  Jianguo Jin,et al.  Coordinated Signaling through Both G12/13 and Gi Pathways Is Sufficient to Activate GPIIb/IIIa in Human Platelets* , 2002, The Journal of Biological Chemistry.

[62]  R. Hipskind,et al.  Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. , 2002, Bone.

[63]  E. Barnard,et al.  Characterization and Channel Coupling of the P2Y12Nucleotide Receptor of Brain Capillary Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[64]  L. Parise,et al.  Relationships between Rap1b, Affinity Modulation of Integrin αIIbβ3, and the Actin Cytoskeleton* , 2002, The Journal of Biological Chemistry.

[65]  L. Brass,et al.  Activation of Rap1B by Gi Family Members in Platelets* , 2002, The Journal of Biological Chemistry.

[66]  B. Nieswandt,et al.  The P2Y12 receptor induces platelet aggregation through weak activation of the αIIbβ3 integrin – a phosphoinositide 3‐kinase‐dependent mechanism , 2001 .

[67]  P. Conley,et al.  Impaired activation of murine platelets lacking Gαi2 , 2001 .

[68]  G. Burnstock,et al.  Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y1 receptor on bone cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  D. Ory,et al.  A Glanzmann’s mutation in β3 integrin specifically impairs osteoclast function , 2001 .

[70]  Y. Imai,et al.  Extracellular ATP or ADP Induce Chemotaxis of Cultured Microglia through Gi/o-Coupled P2Y Receptors , 2001, The Journal of Neuroscience.

[71]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[72]  B. Coller,et al.  Structure and Function of Murine αIIbβ3 (GPIIb/IIIa): Studies Using Monoclonal Antibodies and β3-null Mice , 2000, Thrombosis and Haemostasis.

[73]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[74]  R. Hynes,et al.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. , 2000, The Journal of clinical investigation.

[75]  J P Cazenave,et al.  Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. , 1999, The Journal of clinical investigation.

[76]  K. Rajewsky,et al.  From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. , 1999, Immunity.

[77]  R. Hynes,et al.  Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. , 1999, The Journal of clinical investigation.

[78]  D. Mccarty,et al.  Synovial fluid ATP: a potential substrate for the production of inorganic pyrophosphate. , 1991, The Journal of rheumatology.

[79]  J. Tschopp,et al.  The Inflammasomes , 2010, Cell.

[80]  A. Graybiel,et al.  The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphaIIbbeta3. , 2006, Blood.

[81]  S. M. Sims,et al.  P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. , 2005, The Journal of biological chemistry.

[82]  D. Billadeau,et al.  Protein kinase D1 and the beta 1 integrin cytoplasmic domain control beta 1 integrin function via regulation of Rap1 activation. , 2005, Immunity.

[83]  S. Teitelbaum,et al.  alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. , 2005, Immunological reviews.

[84]  A. Zallone,et al.  c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. , 2003, The Journal of clinical investigation.

[85]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. , 2002, Nature medicine.

[86]  L. Parise,et al.  Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. , 2002, The Journal of biological chemistry.

[87]  B. Nieswandt,et al.  The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism. , 2001, FEBS letters.

[88]  P. Conley,et al.  Impaired activation of murine platelets lacking G alpha(i2). , 2001, The Journal of clinical investigation.

[89]  D. Ory,et al.  A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. , 2001, The Journal of clinical investigation.

[90]  B. Coller,et al.  Structure and function of murine alphaIIbbeta3 (GPIIb/IIIa): studies using monoclonal antibodies and beta3-null mice,. , 2000, Thrombosis and haemostasis.